Visioneering Technologies Beheer

Beheer criteriumcontroles 1/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Juan Aragon

Algemeen directeur

US$400.0k

Totale compensatie

Percentage CEO-salaris	25.0%
Dienstverband CEO	1.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3yrs
Gemiddelde ambtstermijn bestuur	2.4yrs

Recente managementupdates

Recent updates

Health Check: How Prudently Does Visioneering Technologies (ASX:VTI) Use Debt?

Sep 23

Analyse CEO-vergoeding

Hoe is Juan Aragon's beloning veranderd ten opzichte van Visioneering Technologies's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$3m
Mar 31 2024	n/a	n/a	-US$3m
Dec 31 2023	US$400k	US$100k	-US$3m

Compensatie versus markt: Juan's total compensation ($USD400.00K) is above average for companies of similar size in the Australian market ($USD299.27K).

Compensatie versus inkomsten: Insufficient data to compare Juan's compensation with company performance.

CEO

Juan Aragon

1.1yrs

Tenure

US$400,000

Compensatie

Dr. Juan Carlos Aragon has been the Chief Executive Officer and Executive Officer at Visioneering Technologies, Inc. since October 01, 2023. He served as Senior Vice President, Global Professional & Clinic...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Juan Aragon	CEO & Executive Director	1.1yrs	US$400.00k	geen gegevens
Brian Lane	COO & CFO	5.9yrs	US$466.50k	1.97% A$ 130.7k
Kuang-Mon Tuan	Chief Medical Officer	3yrs	US$429.00k	1.83% A$ 121.2k
Richard Griffin	Founder & Medical Adviser	no data	geen gegevens	geen gegevens
Layna Mendlinger	Global Head of Marketing	2.7yrs	geen gegevens	geen gegevens
Leanne Ralph	Company Secretary	4.3yrs	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

Ervaren management: VTI's management team is considered experienced (3 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Juan Aragon	CEO & Executive Director	1.1yrs	US$400.00k	geen gegevens
Allan Rubenstein	Independent Non-Executive Director	2.4yrs	geen gegevens	0.35% A$ 23.4k
Andrew Silverberg	Non-Executive Director	4yrs	geen gegevens	0.16% A$ 10.6k
Kathleen Miller	Independent Interim Chair of Board	1.9yrs	geen gegevens	1.27% A$ 84.5k
Dwight Akerman	Independent Non Executive Director	3.3yrs	geen gegevens	0.32% A$ 21.1k

2.4yrs

Gemiddelde duur

Ervaren bestuur: VTI's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Visioneering Technologies Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Visioneering Technologies, Inc Announces the Departure of Brian Lane as CFO, Effective November 15, 2024

Visioneering Technologies, Inc., Annual General Meeting, May 23, 2024

High number of new and inexperienced directors

High number of new directors

Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Executive Director, Effective 1 October 2023

High number of new and inexperienced directors

Recent updates

Visioneering Technologies, Inc Announces the Departure of Brian Lane as CFO, Effective November 15, 2024

New major risk - Financial position

Visioneering Technologies, Inc., Annual General Meeting, May 23, 2024

High number of new and inexperienced directors

Full year 2023 earnings released: US$0.099 loss per share (vs US$0.23 loss in FY 2022)

Visioneering Technologies, Inc. has completed a Follow-on Equity Offering in the amount of AUD 2.764556 million.

New major risk - Shareholder dilution

High number of new directors

Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Executive Director, Effective 1 October 2023

First half 2023 earnings released: US$0.057 loss per share (vs US$0.13 loss in 1H 2022)

Full year 2022 earnings released: US$0.19 loss per share (vs US$0.11 loss in FY 2021)

High number of new and inexperienced directors

Visioneering Technologies, Inc. Announces Board Changes

Visioneering Technologies, Inc. Enrolls 100% of Subjects in its International Randomized Controlled Clinical Trial Known as PROTECT

High number of new and inexperienced directors

First half 2022 earnings released: US$0.13 loss per share (vs US$0.085 loss in 1H 2021)

High number of new and inexperienced directors

Visioneering Technologies, Inc. Achieves 50% Enrollment Milestone in its PROTECT International Clinical Study for Myopia Progression Control

Visioneering Technologies, Inc. Announces Board Changes

Insider recently bought AU$686k worth of stock

Visioneering Technologies, Inc. Provides Revenue Guidance for the Year 2022

Visioneering Technologies, Inc., Annual General Meeting, May 26, 2022

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Full year 2021 earnings: EPS misses analyst expectations

Visioneering Technologies, Inc. Announces Initiation of the Protect Clinical Trial

Visioneering Technologies, Inc. Announces US Patent Office Allows Key Patent for VTI

Health Check: How Prudently Does Visioneering Technologies (ASX:VTI) Use Debt?

First half 2021 earnings released: US$0.085 loss per share (vs US$0.98 loss in 1H 2020)

Consensus forecasts updated

Independent Non-Executive Director Tom Dooley has left the company

Visioneering Technologies, Inc. Provides Revenue Guidance for the Fiscal 2021

Full year 2020 earnings released: US$0.012 loss per share (vs US$0.039 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Visioneering Technologies, Inc. Launches Education Platform

Visioneering Technologies, Inc. Announces Board Changes

Analysts increase revenue estimates to US$4.70m

Visioneering Technologies, Inc Presents Positive 5-Year Data in Children

Analysts update estimates

Earnings released

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur